Phosphoprotein-based biomarkers as predictors for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Cancer treatment disparities necessitate personalized medicine approaches.
• Identifying predictive biomarkers and targeted therapies is crucial for effective cancer treatment.

Purpose of the Study:

• To investigate the role of Cyclin-dependent kinase 5 (Cdk5) in neuroendocrine neoplasms.
• To identify Cdk5-driven tumor biomarkers and evaluate Cdk5-targeted therapies.

Main Methods:

• Phosphoproteomics and high-throughput screening to identify downstream phosphorylation sites.
• In vitro and in vivo studies using mouse models and patient-derived xenografts.
• Development and testing of biomimetic nanoparticles for drug delivery.

Main Results:

• Cdk5 was identified as a driver of tumor growth in specific neuroendocrine neoplasm subgroups.
• Phosphorylation sites downstream of Cdk5 serve as predictive biomarkers.
• Selective Cdk5 inhibitors and nanoparticle drug delivery effectively reduced tumor burden in preclinical models.
• Biomarkers accurately predicted response to anti-Cdk5 therapy in patient-derived xenografts.

Conclusions:

• Cdk5 is a viable therapeutic target for a subset of neuroendocrine malignancies.
• A diagnostic assay for Cdk5-dependent tumors combined with targeted therapy offers a rational treatment strategy.
• Biomimetic nanoparticles enhance targeted delivery and reduce toxicity of anti-Cdk5 agents.